title: PLGA/polymeric liposome for targeted drug and gene co-delivery.
abstract: Chemotherapy is one of the most effective approaches to treat cancers in the clinic, but the problems, such as multidrug resistance (MDR), low bioavailability and toxicity, severely constrain the further application of chemotherapy. Our group recently reported that cationic PLGA/folate coated PEGlated polymeric liposome core-shell nanoparticles (PLGA/FPL NPs). It was self-assembled from a hydrophobic PLGA core and a hydrophilic folate coated PEGlated lipid shell for targeting co-delivery of drug and gene. Hydrophobic drugs can be incorporated into the core and the cationic shell of the drug-loaded nanoparticles can be used to bind DNA. The drug-loaded PLGA/FPL NPs/DNA complexes offer advantages to overcome these problems mentioned above, such as co-delivery of drugs and DNA to improving the chemosensitivity of cancer cells at a gene level, and targeting delivery of drug to the cancer tissue that enhance the bioavailability and reduce the toxicity. The experiment showed that nanoparticles have core-shell structure with nanosize, sustained drug release profile and good DNA-binding ability. Importantly, the core-shell nanoparticles achieve the possibility of co-delivering drugs and genes to the same cells with high gene transfection and drug delivery efficiency. Our data suggest that the PLGA/FPL NPs may be a useful drug and gene co-delivery system.
authors: Institute of Nanobiotechnology, School of Materials Science and Engineering, Tianjin University and Tianjin Key Laboratory of Composites and Functional Materials, Tianjin,300072, PR China.
authors: Hanjie
authors: H
authors: Wang
authors: Peiqi
authors: P
authors: Zhao
authors: Wenya
authors: W
authors: Su
authors: Sheng
authors: S
authors: Wang
authors: Zhenyu
authors: Z
authors: Liao
authors: Ruifang
authors: R
authors: Niu
authors: Jin
authors: J
authors: Chang
mesh_terms: D002412:Cations; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D004247:DNA / Q000378:metabolism; D004317:Doxorubicin / Q000494:pharmacology; D016503:Drug Delivery Systems / Q000379:methods*; D024202:Electrophoretic Mobility Shift Assay; D005434:Flow Cytometry; D005492:Folic Acid / Q000494:pharmacology; D018014:Gene Transfer Techniques; D049452:Green Fluorescent Proteins / Q000378:metabolism; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry*; D008081:Liposomes / Q000737:chemistry*; D008856:Microscopy, Fluorescence; D053758:Nanoparticles / Q000737:chemistry; D010316:Particle Size; D056951:Photoelectron Spectroscopy; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D015203:Reproducibility of Results; D013499:Surface Properties / Q000187:drug effects; D014162:Transfection
chemical_list: D002412:Cations; D008081:Liposomes; C485184:enhanced green fluorescent protein; D049452:Green Fluorescent Proteins; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D004317:Doxorubicin; D004247:DNA; D005492:Folic Acid